Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. (Q34633525)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

main subject

phase III clinical trial

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Dror Michaelson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Robert Motzer

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

5

Cezary Szczylik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Brian I Rini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Piotr Tomczak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Thomas E Hutson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Vera A Gorbunova

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Martin E Gore

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Igor G Rusakov

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sylvie Negrier

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Yen-Chuan Ou

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Daniel Castellano

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ho Yeong Lim

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Hirotsugu Uemura

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jamal Tarazi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

David Cella

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Connie Chen

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Brad Rosbrook

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sinil Kim

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Bernard Escudier

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

4 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

378

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1931-1939

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

9807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Metastatic renal cell carcinoma: many treatment options, one patient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Axitinib for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sorafenib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Development and validation of a scale to measure disease-related symptoms of kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961613-9

7 January 2021

10.1016/S0140-6736(11)61613-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22056247%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference